<SEC-DOCUMENT>0000950170-25-068599.txt : 20250512
<SEC-HEADER>0000950170-25-068599.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512081146
ACCESSION NUMBER:		0000950170-25-068599
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MBX Biosciences, Inc.
		CENTRAL INDEX KEY:			0001776111
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42272
		FILM NUMBER:		25932703

	BUSINESS ADDRESS:	
		STREET 1:		11711 N. MERIDIAN STREET
		STREET 2:		SUITE 300
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
		BUSINESS PHONE:		3179893100

	MAIL ADDRESS:	
		STREET 1:		11711 N. MERIDIAN STREET
		STREET 2:		SUITE 300
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbx-20250512.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-12T08:10:30.3178+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:mbx="http://www.mbxbio.com/20250512">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_14feceb8-263c-4ba7-aac0-911ea583a68a" name="dei:EntityCentralIndexKey" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae">0001776111</ix:nonNumeric><ix:nonNumeric id="F_a1abfb2c-b3ba-4104-87e4-09e133dfc0cc" name="dei:AmendmentFlag" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mbx-20250512.xsd"/></ix:references><ix:resources><xbrli:context id="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776111</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-12</xbrli:startDate><xbrli:endDate>2025-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bd2b62c-5280-4ec7-845a-c27a0fc2f5f2" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_e8b6a3f0-ac67-4d9a-9ad8-8b127c5dc86c" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">May 12, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf0508f6-44ea-45bc-aab3-63603e9e8750" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MBX Biosciences, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_911061c5-58e6-44d7-bb26-fea7be4eaf07" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_304e1cb4-5e2f-4409-b076-e3e281277204" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-42272</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b1540042-1216-49ff-a146-fb6037d5092d" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84-1882872</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_91bad831-75cc-426a-a255-b771d3d03835" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11711 N. Meridian Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_037c6834-940d-4a4b-8132-260bb7184439" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_db071b1b-cfcf-48cf-9c59-fc8f834fef46" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carmel</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_bc83cff3-3739-43c2-a131-a8dfd1217c87" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Indiana</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3ddd05c6-9d8e-4d7f-bdbd-47d65b9e14e2" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">46032</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_ab2e7df5-f1f6-41c3-afea-1c5e8a0a5e43" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(317)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_ad307157-696b-410f-aa8a-461fa64ddc2b" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">659-0200</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a8f7be3a-a610-4412-a254-157376cdbb1b" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Not Applicable</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21a4ed9c-349d-464f-bfea-c09783890365" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e6b3944-da1e-4674-84b3-0cebaf274f60" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8163d684-5bb9-4720-ac29-e549c1449029" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37fab33e-8604-4002-82c5-1b7c51ca0a46" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e183e9c7-867e-452d-8349-63c90ffcc61d" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c9987eb3-c026-44a2-af05-35f5050ffd8b" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MBX</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_80c324f1-b81b-4de5-8349-3c9da1edec6e" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_8f851a02-b585-4978-a9b1-5edb65ff8fbc" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_8c95cef3-e886-4f2f-be78-1e440476fb4d" contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 12, 2025, MBX Biosciences, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information included under Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto), is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:21.92%;box-sizing:content-box;"/>
     <td style="width:78.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mbx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release Issued by MBX Biosciences, Inc. on May 12, 2025</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MBX Biosciences, Inc.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 12, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ P. Kent Hawryluk</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer (Principal Executive Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mbx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:1.107%;font-size:10pt;margin-top:13.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img258572290_0.jpg" alt="img258572290_0.jpg" style="width:242px;height:96px;"></p><p style="margin-left:1.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Topline results for the Phase 2 Avail&#153; evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Investigational New Drug submission for MBX 4291 on track for 2Q 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">$240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) &#x2013; MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;We&#x2019;ve followed up on our strong execution in 2024 with excellent progress on all our programs enabled by a strong balance sheet and cash position,&#x201d; said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. &#x201c;Following full enrollment of the Phase 2 Avail trial investigating canvuparatide for the treatment of</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">hypoparathyroidism, we look forward to reporting top line results in the third quarter of 2025. We&#x2019;re also on track to submit our investigational new drug (IND) application this quarter for MBX 4291, a novel glucagon-like peptide 1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug for treating obesity. In addition to these milestones, we also expect to begin a Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia patients in the second half of this year and share further details on our additional obesity candidates currently in pre-clinical development.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">First Quarter 2025 and Recent Corporate Highlights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Hypoparathyroidism (HP): Canvuparatide (MBX 2109)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Phase 2 topline data from Avail trial expected in 3Q 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> MBX completed enrollment of 64 participants, exceeding its original enrollment target, in the Phase 2 Avail trial of canvuparatide, a potential long-acting parathyroid once-weekly hormone peptide prodrug candidate, in the first quarter of 2025. Topline results are expected in the third quarter of 2025. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Obesity: MBX 4291</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">IND application submission on track for Q2 2025: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX 4291, a GLP-1/GIP co-agonist prodrug, is being developed as a once-monthly treatment for obesity. The Company expects to submit an IND application for MBX 4291 this quarter.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Post-bariatric Hypoglycemia (PBH): MBX 1416</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Phase 2 trial expected to be initiated in 2H 2025: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In January,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX reported Phase 1 top line results for its MBX 1416 long-acting GLP-1 receptor antagonist</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">developed for the treatment of PBH. A Phase 2 trial is expected to be initiated in the second half of 2025 following completion of an End of Phase 1 meeting with the U.S. Food &amp; Drug Administration (FDA).  </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Corporate</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">New Independent Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: Earlier in April, MBX announced the appointment of Steve Hoerter as an independent director to the Company&#x2019;s board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">As a veteran executive with a wealth of pharmaceutical leadership and commercialization, as well as extensive board experience, Mr. Hoerter will be instrumental in supporting MBX Biosciences during the next stage of the Company&#x2019;s growth.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">First Quarter 2025 Financial Results</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents and Marketable Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: As of March 31, 2025, MBX Biosciences had cash, cash equivalents and marketable securities of $240.8 million. Based on its current operating plan, management expects the combined cash, cash equivalents and marketable securities balance to fund operations into mid-2027. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">R&amp;D Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: Research and development expenses for the three months ended March 31, 2025, were $22.4 million compared to $11.0 million for the same period in 2024. The increase of $11.4 million was driven by costs associated with ongoing IND-enabling studies for MBX 4291 and the ongoing Phase 2 Avail trial of canvuparatide.  </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">G&amp;A Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: General and administrative expenses for the three months ended March 31, 2025, were $4.1 million compared to $2.3 million for the same period in 2024. The increase of $1.8 million was driven by increased personnel-related costs as the Company expanded its infrastructure to support its growth in operations.  </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">: Net loss for the three months ended March 31, 2025, was $23.9 million compared to a net loss of $12.3 million for the same period in 2024. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"></font>&#160;</h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About MBX Biosciences</font></h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP&#153; platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company&#x2019;s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND filing anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About </font><font style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX&#x2019;s Proprietary Precision Endocrine Peptide (PEP&#153;) Platform</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide&#153; (PEP&#153;) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.</font></h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"></font>&#160;</h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This press release contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences&#x2019; expectations regarding the Phase 2 Avail&#153; trial of canvuparatide, including the timing of topline results; the expected timing of the IND application submission for MBX 4291; statements related to MBX 2491 being developed as a once-monthly treatment for obesity; expectations regarding development of MBX Biosciences&#x2019; additional obesity candidates currently in pre-clinical development; the expected timing for the Phase 2 trial for MBX 1416 in PBH patients; statements related to the ability of MBX 1416 to be a treatment of PBH; statements related to the contribution of MBX Biosciences&#x2019; leadership and board of directors; and expectations regarding MBX Biosciences&#x2019; uses of capital, expenses and financial results, including the anticipated cash runway timing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward looking statements are based on management&#x2019;s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences&#x2019; business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company&#x2019;s research and development activities; MBX Biosciences&#x2019; ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company&#x2019;s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences&#x2019; ability to attract, integrate and retain key personnel; risks related to the Company&#x2019;s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences&#x2019; intellectual property protections; and risks related to the competitive landscape for MBX Biosciences&#x2019; product candidates; as well as other risks described in &#x201c;Risk Factors,&#x201d; in MBX Biosciences&#x2019; Quarterly Report on Form 10-Q for the three months ended March 31, 2025 filed with the Securities and Exchange Commission (SEC), its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, as well as subsequent filings with the SEC. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Securities Litigation Reform Act of 1995.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Media Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Katie Beach Oltsik</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Inizio Evoke Comms</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">katie.beach@inizioevoke.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(937) 232-4889</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Investor Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Jim DeNike</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">jdenike@mbxbio.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MBX BIOSCIENCES, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SELECTED FINANCIAL INFORMATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Operations Data</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"></td>
     <td style="width:1.62%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.62%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended March 31,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Condensed Statements of Operations Data:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(in thousands, except per share and per share data)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,405</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,049</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,124</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,265</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,529</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,314</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,529</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,314</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,649</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23,880</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,337</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.71</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10.26</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of common shares <br>&#160;&#160;&#160;outstanding used in computation of net loss<br>&#160;&#160;&#160;per common share, basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,412,386</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202,396</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheet Data</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"></td>
     <td style="width:1.62%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.62%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Condensed Balance Sheet Data:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240,786</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,149</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Working capital</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233,795</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,235</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,926</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268,535</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,504</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,093</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible preferred stock</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(161,385</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(137,505</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,422</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,442</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Working capital is defined as total current assets less total current liabilities. See our financial statements and the related notes thereto included in our Quarterly Report on Form 10-Q for the Three Months Ended March 31, 2025 and our Annual Report on Form 10-K for the Year Ended December 31, 2024 for further details regarding our current assets and current liabilities.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img258572290_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img258572290_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "K ;$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;X*_'"_V0:?X*\0:M#J/ASQG=X;,7@3Q:;;3DO\ 4I @E'AG6-/TK6B91!I
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M$?U%X-?\(D,/AZWN?VY!UJW-HHUG%3P2?7^#'V:B]JN(EHKL^"?^#AS]H_\
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MO<7NI:IJ=_+!9V%C:01O-<W5U-%!#$C/(ZJ":_AT_P"'W_\ P45_Z*SX6_\
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M_P"7G+%+!+)!/')#-#(\4T,J-'+%+&Q22.2-P'CDC<%71@&5@58 @BO[,?\
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MB_>A#!X>K]8^KOK[&4OJ^ CM:-6"5K7/WL^+O@"S^*_PH^)OPNU!HTL?B/\
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MO"/ARREU/Q#XIUS2?#FA:= "T^H:SKE_;Z9I=E"H!+2W=]=001@ DO(!BO\
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M'_%>A:OX;UVP9WB6]T;7=/N-+U.T:2)DEC%S974\)>-E= ^Y&# $?R?^.?\
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M4DL."M])I>L+!(2IT^X4;V_H0_9-_8<_9V_8O\,W&A_!;P?]GUK5;>*#Q/\
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MN1U.&,.^>ADD\OH2P-"KSU*GUBE2<+T\4ZE6K4EBX26)E4JU9RJN52;E\/\
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G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mbx-20250512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-12T08:10:30.6310+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.mbxbio.com/20250512" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:mbx="http://www.mbxbio.com/20250512" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mbx-20250512.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MBX Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001776111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1882872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11711 N. Meridian Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-0200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not Applicable<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '9!K%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( '9!K%JT*Z+^[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=ZZR38.49<+B!-(2$P"<8L<
M;XMHVB@Q:O?VM&7KA. !.,;^\_FSY!JCQB[1<^HB)?:4;X;0M%ECW(HC<]0
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ =D&L6CJJHN=
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " !V0:Q:1L=-2)4   #-    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '9!K%JT*Z+^[@
M "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( '9!K%J97)PC$ 8  )PG   3              "  > !  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ =D&L6N6]$8RQ!   BQ(  !@
M             ("!(0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( '9!K%J?H!OPL0(  .(,   -              "  0@-  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ =D&L6I>*NQS     $P(   L
M     ( !Y \  %]R96QS+RYR96QS4$L! A0#%     @ =D&L6CJJHN=  0
M/ (   \              ( !S1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( '9!K%HD'INBK0   /@!   :              "  3H2  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( '9!K%IED'F2&0$  ,\#
M   3              "  1\3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  &D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbx-20250512.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="mbx-20250512.htm">mbx-20250512.htm</File>
    <File>mbx-20250512.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mbx-20250512.htm": {
   "nsprefix": "mbx",
   "nsuri": "http://www.mbxbio.com/20250512",
   "dts": {
    "inline": {
     "local": [
      "mbx-20250512.htm"
     ]
    },
    "schema": {
     "local": [
      "mbx-20250512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_8a5ee7b1-45cc-457e-b324-b455cba57aae",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mbx-20250512.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8a5ee7b1-45cc-457e-b324-b455cba57aae",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mbx-20250512.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.mbxbio.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-068599-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-068599-xbrl.zip
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MGH00ZD\<?W$^ $74-IV*INX<>Z%.N]@A'NI\.D>F932AX*W$4$>S+8G+[JO
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MBR'F,BM14@7*!KUDK[Z35GV]?ZGFOP=Y(:-1W:LNA8&,YMRVV1W[HRH(E]<
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MVR2ON=VTZOGB#O$ZOPO[VUGG!MA%!8&Z!1Y((N1PE6@8G%:@ 8L[$#XF%5?
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MIEU+^:(C1<KJE%]=?$S1J2;QL.FIBKITBYZW2*M(2P'"8\0^7WY.2\N!;#
M1</*DA5@)K,-<';^#9XP@%W)620C$M;CT1:RZ[&_OVW>VK99WGTP8C>PL#[I
M=39_#E/M8G3^R7A 67D^G9G:YK7H)S _A?2+8/[P<H7%P!BR!\W!#),0^H1^
M?5J$4 C?NA0#;+N0:F==C*  HE:8A.1AG)CY^( MGS/HI$'B8QF!!:F^\RGN
M#;0*TXH'<S*'449D!GN!'SKCT*JYK=Y73H&B4,?M-B;;):,@S,LC( %ZL$9X
MQ,S->)+CS!9[;FJ33'J2W!! :LJ,3,.-TH2<B0/281(8&073+#]1=6&V1,,,
M]UF.ASXN8'N)@$HT21YR3&3$$UL=@CS7H@)\3V;%#6P=,V$9W(HN7 *&-.SV
M]K8V[-[!;JW!_J3QV(@HAG4\0O9>AM?"OPIKI19BJPN'GR/.7"Y0:;0GETFR
MYYDD^ZE:WF,YMNCGZ0<&LG"L#WPNJEVYKG:9*SZ?L\)+N4YVP#ZG2MGJ Z!7
M%JY5;F-F=;H[&O@]E9#QWQVQ?J"ZX]BO+$;,:![&N&#6:4JZ)O<&Z +(E'*J
MN@"*$LQL6I>OL??PA^9]&\:5QFIK(V/04XJJB7T]=5I&#^.K5,TO<E>F\N/P
M4-,"W8:,!G8M1BR00VG2<W+0&T%!5CYHRYA^C!IZ]L>LK4&G2HK)(>K9@HV5
MML1@!_:!&&X'(,I1RR/]JW#LCWIK5MFKAA:*+381BP#5!Z#6"+1[H)$0J7=E
MP*$?!>,8PFK[T^%Y2!\D(A8ALUJJI.*!QCIRX"U!"0AH.&G5PY)E:1Q?&,O8
M4$ E5<K C.O09+$#M.*H D8H)8VJ&JV2_F#R,4;_0,>%QF!-59RZEZWI F.(
MXP3'1R8'5BSL:?%G0ET#P(?]VF9WVYI#/YUWY.>WMNI@];U2U\B>7V'KT6[8
M)Q?)-X2\B"IV@CI#L)#J/G%>(S,MSU@-4D+%.:'RXIRX,]-<EJ'@(94I[&'@
M%>W(YLEY%A,[CL5BYQY9QXVS5HLV8?YTXW+.TY=WWH"'?5%X[;#"!"(]1F,/
M"5FL28H._O'HQ_;ON)9H=J\K @GP/WL#:2##9.Z=)/!G+V-)R>'</FQ$U>QU
MB4LPIZ4A'\U>I#BMV:N9CV3.+8U^E3G= M[^,7<\\6#^S-)223/7;_'Q_&HJ
M8&3 -:(M,A1!-DH1.U,K-ZA:*PJAQ4Q5P2^D# C80V6HBNSBAS-N3:M?9LU3
M.A2R 7%$+.YK(76C5%@7-%H<+_9*HIB&7,GFPS"/#D4H7"Z\KD4?&L:--NUI
MS?30-*@N%6+Y\PN_.+&H_M18DI*+"49HMYF9+!/5H=OCE+/Q<W#YGKHMQ3B5
MSN0,[6$N+!_YSP[/&LO61UE(BRGWZB)*KJ!FZ'SR3'\!9'YAU,^OW^5JTB(2
M4?)(5P8XMG0F]+I-_>,S"8/WM8/,K64WR7+_%I%E*AUB-M?$;M %M%_4:A+;
MF%(/E$R#WML\((&\<=/5QJ<9M.AXI-A1G82W?)12W%41WR$M(E6EV!QT14#-
MCT+&%L?81L^"DB>8DQS?:( DW3_2TL5:QM?V!B9I:01]4@S(%4Y2F86BSU-K
MA?=Z^-XBUNXFH.(#IE<*L= Y&X\Y&[-R;7UEDF]&>==X")*(&GO+:6,5N_<X
M[!@&UY-""7X8.9AM/:$9J@=(5Q@=55T$&8?:5HY9DXYZDDGM=-;6TT1%L>=G
M%NE%D95H9=V0!C7S$80QJ*9H952:@26R8RL*11+]46%GJRY2/MOC:#))<MG/
M.>Z)LY.T(MC2^0Q 10^=_!AZ,;6<Q:GB\5J&X&0>SH'SB1G.I4V6I.<).QZL
METCU(@6M#JYQ JR2-T[0'U-4?-+C-BPI-?KM@V.!4Z#V3![:HI?LW(E$PG_0
MHG"#]=2H6B4L!A4TQLZT(,4''0=YX%6GR#!C.3)#DT4LCJ=P)/5@X\7XN41\
MI"!T,9J?2G^3[]B2SQ;E7+ F<\C"9XDR19.9.128J]!-"A,IMV&K0,!49DVF
MP>-S\Y+@T\&ABH49##!Q@3ZB(B\GL$UUREXSX\I//^U!&Z9#R##;'XM6%E<Q
M0+]*,O:4C/ 78PV@5%C/74@<K#"2/%U@$O@QR&:1JRGS>IMEP$[QZ$]197;;
MER]B#[0->X:7J?E?X%8&=F,C !Y8U&&:\@: 9K_)AYON+7J\&O7J;P\/[\'C
MRRR\>LH41.KDYB"P=J; OOAZ>7%0H6UW'H8)Y=E-C^#7? 14I-[V_$9X8M@%
M.J2='\YT?GDQ<6"*NR-U%ME3UGCBV=I,.D]J0@3D?/,"+H<X#5 0@7OLEPC0
MNJ"4?\.O4_C+#/(H@:<\DA CED06>NB$_49:*PM!(KS/ILK,))@4K+>0H6V_
MAVQ(KZ;4E!;W)V0QE07)GJ#-#UN0[+0<.^@A3VHO&2)JX(PQ3'0@22*-@%[P
M2SZ:_*S85NJ-#)*4)(FVCMZ WU92P"=*(5G'^R/;WC'O"3;@NJOLQQD>-/NL
MX*^6-X7Z!YO3G-C"8REWH.L.=-V![MZ4!GQ:V"E(T_<R^Q@.B$LZFLH]K&='
MSDK?H45'I23)W#?6*9M90.3LQM_1@D4-P'[#%*3J%]H3=/J6!6>AJP^]_+%U
M,8$^0P=FN8'+8!169\'L#GLRFRK;**?)8ACE!:NPM[01M+3&&E%L]2$8 6GC
MV,3;-S7@3D^1WRH85=*/.:$=;MW7J%%*DVIXJ=7S/_?-ADKP%[^B-"Z[-=G$
MQ!D)Z#Z@YF6Z7R75T)"08.B3I8D!DW@##?,PU:2L3@,=>SPVI?Z,WO;7$M[P
MV>('X4L.W -+[YGV-A!B-?/^%9WC[#4=RWT*3"RO]V?N5R&H88I=WJAK:Y9N
MM+[+T\[]&M>]UL5U_Z<D.@@D X;NELS&VNUU>''6.CE@S5:S>GAZ>E9B";-'
MRMNZOL"1Z33[)V7^)8?LC?@HK\7^S'E1%M?.3_P/7X2PTO\<)X/LN439+63%
MP$VA2^M+<EY8YX5U7MB=],+.1YY':G6K(R\)_*M/7R^N+C]>7'ZML*N/%T_F
M,RHY;;Y>OK^\^';YAKV]^GC^\>+J_#U0Y^VG+Q_.OUU]^KB_HLO-=E\VP/AL
M6_78IW%YS3?<<$<CZPNYPK-^E<08)Y.'&L0#C"ND]':AT[_P2\@'CFJ6:O\.
M>>)C[/N34:0<NN;<JK.-6J.^PU5G05=CK]+JO;.3)_TY56=Q4-@^S $?KX*Q
MHY+TD;S@5:W^/'L>^#G@42S:L: $AKQF&"FM]CU2P7$ N7*/\4PV[K&=-9 ]
M!8_YDQ6VCH]K9V>MYT7=.],S4^7[I?$7O=RH'3>7?779]YJUT]-6??RS=$-N
MS@O>@]_T#%-EAAONW"[WKOL:4XJK*>+VZ&<^XA8JQ5D+$B_,8\A)V[%.-F)Z
MB792'2[<8$*LQX-T_UM,F/$5%-ZT.R5MKL01*4O$N<U;YTW1\'0C@+ZLA3U!
M.5@A:#O\Q[/C9VNA8N[*R/Q8J#_AQZA8QA5SZ3R'*&ND^XKUJ0=FS2Z.7GY:
M1K]GB2RRU5OE7:3U;8\M$@3PZ"Y(@>4VTH7"S!S,#KO7HFV70'K,Y>82N7=7
M*U&:3J(\Z4; E!<G.4H@.38&*KM*2P<IFX.40P<I)=@&]RFCIW-U40](U?.V
M41==IS6]4H?$"SGO=&!\)O W)P2;EQ=."764W0:]QE%S&YV_;HL[IMQO:CH7
M8BGUMD]YO28Q]14WMQ<<9F\G91TUMY*:3BUS3%DZIMQU:BZAEF7>M$=H8#1?
MS%0(TU[F3G!=>MID1.+I4?:!S71 ]:>*3URI(K?H8^#+[*&E5L-MK&5)'*IU
M$'CCELG#R?BC8]+[F'2E.-%L5@[K2YV-[R3+/O5>7Q>G[I[RO&>,Z+"S_-C9
M:%3JAV>.95>)G8_P"SL#I$P&R"\B%#JM+,\+=<%OA$.HW3=!E@P;VU;4>EKN
M?7Q,WJY(X,-*8[DHO*=B]OL#\QR[;Y-^XY#9L:I#YH?ZE2K-X\V[E?8.F3=S
M?O.DUM(V&D/?E,%O*JXDN,:90D[@EAB!G,#=D, ]KAPU-^^,W#N)6P*T=K:0
M@^;RL:J#YOR<J%5I-9R;:AN,H16<)3ECZ&]6[+V*8_N-9I77(2D!7I48C79#
MVI:%F;=0EI:8-U>;-EX2*Z8LK+IL%-!2R?3.5''@Z<!SB\&S)'9&65AUM>#I
M3E9*:4Q<X=X5L:$X,V4&0C,9>FHH*BP4+MME#\P*Y\1S3KPG"6@X+D&L]][Y
M\$H ULYF<<A</E9UR)PMR=G)29E9?3=QV>7I[$B>SD=A6*!B=P*S=Z92L]9$
MF/)5@E^H*IM(WN8$V*7I7 YF7_&13JMR>EHO-^^73D:[@Q]G1#G,=IB]J9.D
M9J75*IM5M5^8[<Z;2FTNT=<+/#4<JM!^Q*#"NCR6GJVW)H/$"+\$J%9BQ'+B
M>5L RHGGDHGG>NVD46[.WW'A7 (0=P:50VR'V-N"V(UZK7E<;M;?<<AVR4"E
MM*=^IQ40/N- !-X7+$R&73"M5&_"NHK9JZY.)4CQ_RHQL0&3"_IA"7[H6(;X
M7I08RBO"9L+L@&MN \Z,<V;<EBD%6Q^LLM^Z0*M5.43_ZJG3!W:>[\M".@?2
MCED=2']/R89*LPX8?>8P>I.QA? +AWDN#,%KU$^>/U70W6*&LGTWH.]B=^=:
M\N!1&+O?DU[##+_WR_3CWN_K<+MF^U"4O+6>D:X*_/40XS4/>.@)]G4@P$!_
MPPUWA+&^PJN0F8%*8A[Z\8$CBB7*OT.>^-"]_V04*1D>[I$0(-%/DG_>Y'EB
M5*85X:"P?9@#/EX-^$@EZ2.VJT8=E*'GV?/ SP&/8M&.1<0U-R*CA=6;Z+UG
M,U[B&QG+K@RD&;6S!N:Y?VV'Q\>UL[,6]GB'],'1I5,%@M\A;>>JD>EH:\?-
M95]=]KUF[?2T51__+-V0F_."]^X[>C@MU:?.E_= 9\ Q!Y%/RRFB'H1-K%S?
MG-T8E;?\R\B/3Y;<4?[^0-^(;34J3\OG2Z=+EF%%=N5;UNNEW0;<T Y%-H0B
M;X0GZ-3> 4DY@.0I-,Y9"NX<ANVKQKE;FZ',LF'W^+=9;R[UW:<-R( =9','
M$0XBM@$BEJI2ZB#"J87E12>G%F[79IC$_./U8'YIZ+A>[GPA%YU9.U9=,V[_
M32V ISY!VI'<E>6VP87"2G"8AC(;W=)>QZXH.;6W0F'?;QHZNFVEH;W-I%NW
MG5WB&/5=8<I=IZ9+%BYELO %CP<5YL'_F?@SD3<\@.LQY>K"L*Y%&C,HO$1+
M(Y_P\^HE7X3=2/\J"S6WN2A'B=%\M5_K.*Q73DJ085L6GGWJS>YR9QUX.O#<
M5O \;E8:)?C845EX=M,^7&=2K+'^D-+7\! 8%9$T/,B6;G%_.)WJ8>WX]*SX
M<[3H6R1CFAS73N"A2,42*Q.UM0BXD3?B>TY9&D]7C;#D/."$<ND SLGBM<CB
M5JMR<K941)UCU1*SJL/,+:?FKC#B+F+FT7&EV7*8N6G[Q1V)K-]^^:; :F$\
MCH5QQQU.T)45/9R@6\\IQU'EK 1UQ1VK;CWI'&8Z1MP/S#P^K1PYXV#CQH$[
MW'@JXR"0G*J7N8 H)^W*"R%.VJT# 1KURE%]J61;QZDEYE0'F5M.S5UAQ%V$
MS$:E?M9RG.H.#\JX'*O-IU AS1ZS)N#UGM!:($&5=^TL!2?V2@HF3NRM PM^
M^N&N66\<.E[=-5YUH+GEU-P51G2@Z7C5G29LK[5P[GG), DX?JW9%SWI2>.L
M!"?P2@HB3N"M P->-(X;E=:I.SZ?3]V'$_+I,KG*3T.'G@X]]P0]6R>5H[I#
MS_6@ISME**7=8*.0Z%1AH )?Z-B:S6<=JN)D1LZ*<'+0R<$]DH/-UE'EL-ET
MK+ICK.HP<\NIN2N,N(N8>712.3QTF+F>DP;X!6N'[N?WUDMK7N0?;;BO[^\Q
MOP_85+TG)F,ZRPB%SWC,#)DJ7J(UO)%F5;- Q--W"BD5-?95"*82S: 5'GJ2
M;!UNQ#"O36L&@E&Y)^@D5 9&#U>T,(K)T L2'R[+D)KX+>$:T"H8L2\B4MHP
M%;*W2@]9HU[]C?64IK:^#31T^0'F-8C998CO?\B^X\OP^VO4*[9W'H8)C&>V
ML5_SQOY7<)TV4OR,)[9S2 _U$HW#!3(9+H,89M+G&B& >IBB%78\CT@3N\^7
M-[CI7L&_&4?\594PA+MVL],+Q%W5EUIX5"8+6"49AAU?QE' 1VV\.X-*M2.
M(%STS-:'/_](8B-[HVSUZ<6J"/TY!;@*7W#/OQ-U5RY=9ET;/U^*@9["/1D&
ML"FJP,G:M'EB5&?R!I#27HYX7UC7297W@'?;/+CEHYB<)Z]>=I4_^OF_7KT<
MF&'P\_\#4$L! A0#%     @ =D&L6KJ.M#V?$P  1K(  !
M ( !     &UB>"TR,#(U,#4Q,BYH=&U02P$"% ,4    " !V0:Q:P9D_/_D(
M  !+:0  $               @ '-$P  ;6)X+3(P,C4P-3$R+GAS9%!+ 0(4
M Q0    ( '9!K%K+W$24(QX  'VR 0 .              "  ?0<  !M8G@M
@97@Y.5\Q+FAT;5!+!08      P # +@   !#.P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>mbx-20250512_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbx-20250512.xsd" xlink:type="simple"/>
    <context id="C_8a5ee7b1-45cc-457e-b324-b455cba57aae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776111</identifier>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_14feceb8-263c-4ba7-aac0-911ea583a68a">0001776111</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_a1abfb2c-b3ba-4104-87e4-09e133dfc0cc">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_6bd2b62c-5280-4ec7-845a-c27a0fc2f5f2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_e8b6a3f0-ac67-4d9a-9ad8-8b127c5dc86c">2025-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_bf0508f6-44ea-45bc-aab3-63603e9e8750">MBX Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_911061c5-58e6-44d7-bb26-fea7be4eaf07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_304e1cb4-5e2f-4409-b076-e3e281277204">001-42272</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_b1540042-1216-49ff-a146-fb6037d5092d">84-1882872</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_91bad831-75cc-426a-a255-b771d3d03835">11711 N. Meridian Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_037c6834-940d-4a4b-8132-260bb7184439">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_db071b1b-cfcf-48cf-9c59-fc8f834fef46">Carmel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_bc83cff3-3739-43c2-a131-a8dfd1217c87">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_3ddd05c6-9d8e-4d7f-bdbd-47d65b9e14e2">46032</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_ab2e7df5-f1f6-41c3-afea-1c5e8a0a5e43">(317)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_ad307157-696b-410f-aa8a-461fa64ddc2b">659-0200</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_a8f7be3a-a610-4412-a254-157376cdbb1b">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_21a4ed9c-349d-464f-bfea-c09783890365">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_6e6b3944-da1e-4674-84b3-0cebaf274f60">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_8163d684-5bb9-4720-ac29-e549c1449029">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_37fab33e-8604-4002-82c5-1b7c51ca0a46">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_e183e9c7-867e-452d-8349-63c90ffcc61d">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_c9987eb3-c026-44a2-af05-35f5050ffd8b">MBX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_80c324f1-b81b-4de5-8349-3c9da1edec6e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_8f851a02-b585-4978-a9b1-5edb65ff8fbc">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_8a5ee7b1-45cc-457e-b324-b455cba57aae"
      id="F_8c95cef3-e886-4f2f-be78-1e440476fb4d">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
